PURPOSE OF REVIEW: The purpose of this review is to present the most recent advances in the diagnosis of the more common leiomyosarcoma (LMS) anatomic variants, potentially useful prognostic markers that have recently been identified and the systemic approaches currently used or under evaluation to improve the outcome of patients with this disease. RECENT FINDINGS: Over the last few years emphasis has been placed on incorporating effective imaging tools and using pathological biomarkers in the diagnostic workup of LMS. Moreover, efforts are being made to identify meaningful prognostic and predictive parameters that will aid the development of effective novel therapeutics. The number of systemic therapies available to treat LMS has increased over the last decade, but the selection of systemic therapy is not based on the anatomic origin of LMS. SUMMARY: Currently, the only curative option in LMS is surgery and despite progress in systemic therapy the outcome of patients with advanced/metastatic disease remains poor. Better understanding of the underlying biology of the LMS variants, improved diagnostics and more effective, less toxic therapeutic agents are required.
PURPOSE OF REVIEW: The purpose of this review is to present the most recent advances in the diagnosis of the more common leiomyosarcoma (LMS) anatomic variants, potentially useful prognostic markers that have recently been identified and the systemic approaches currently used or under evaluation to improve the outcome of patients with this disease. RECENT FINDINGS: Over the last few years emphasis has been placed on incorporating effective imaging tools and using pathological biomarkers in the diagnostic workup of LMS. Moreover, efforts are being made to identify meaningful prognostic and predictive parameters that will aid the development of effective novel therapeutics. The number of systemic therapies available to treat LMS has increased over the last decade, but the selection of systemic therapy is not based on the anatomic origin of LMS. SUMMARY: Currently, the only curative option in LMS is surgery and despite progress in systemic therapy the outcome of patients with advanced/metastatic disease remains poor. Better understanding of the underlying biology of the LMS variants, improved diagnostics and more effective, less toxic therapeutic agents are required.
Authors: Nathan D Seligson; Esko A Kautto; Edward N Passen; Colin Stets; Amanda E Toland; Sherri Z Millis; Christian F Meyer; John L Hays; James L Chen Journal: Oncologist Date: 2018-12-12
Authors: Mercy Varghese; Oyvind Bruland; Anne Marit Wiedswang; Ingvild Lobmaier; Bård Røsok; Robert S Benjamin; Kirsten Sundby Hall Journal: Clin Sarcoma Res Date: 2016-02-24
Authors: Zhijie Wang; Naiyi Shi; Aung Naing; Filip Janku; Vivek Subbiah; Dejka M Araujo; Shreyaskumar R Patel; Joseph A Ludwig; Lois M Ramondetta; Charles F Levenback; Pedro T Ramirez; Sarina A Piha-Paul; David Hong; Daniel D Karp; Apostolia M Tsimberidou; Funda Meric-Bernstam; Siqing Fu Journal: Cancer Med Date: 2016-11-23 Impact factor: 4.452
Authors: Eda Machado; Shai White-Gilbertson; Diantha van de Vlekkert; Laura Janke; Simon Moshiach; Yvan Campos; David Finkelstein; Elida Gomero; Rosario Mosca; Xiaohui Qiu; Christopher L Morton; Ida Annunziata; Alessandra d'Azzo Journal: Sci Adv Date: 2015-12-18 Impact factor: 14.136
Authors: Yael Babichev; Leah Kabaroff; Alessandro Datti; David Uehling; Methvin Isaac; Rima Al-Awar; Michael Prakesch; Ren X Sun; Paul C Boutros; Rosemarie Venier; Brendan C Dickson; Rebecca A Gladdy Journal: J Transl Med Date: 2016-03-08 Impact factor: 5.531